Tin Sulfide Quantum Dots for Low-Toxicity NIR Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing near-infrared (NIR) quantum dots for in vivo imaging often rely on heavy metals, which are toxic, and existing tin sulfide (SnS) quantum dots lack sufficient photoluminescence and stability for effective biomedical imaging.
Innovation Solution
A method involving the synthesis of tin sulfide quantum dots in a water-miscible solvent with controlled pH and capping molecules, followed by peptide bond extension and neutralization, to achieve stable and low-toxicity NIR-emitting SnS QDs suitable for in vivo imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Illumination intensity
If heavy metal-containing NIR QDs (CdTeSe/CdS, InAs/InP/ZnSe, PbS, CdHgTe) are used for deep tissue imaging, then photoluminescence properties and imaging capability are improved, but toxicity increases
Solution Approach 1:
The patent changes the material composition parameter by replacing heavy metals (Cd, In, Pb, Hg) with non-toxic elements (Sn, S, Se, Te) to synthesize NIR QDs that maintain photoluminescence properties while eliminating toxicity. The specific composition SnSxSe1-x with controlled stoichiometry achieves both low toxicity and desired optical properties.
Solution Approach 2:
The patent creates composite quantum dot structures with core-shell configurations (e.g., SnS core with protective shell) to combine the advantages of different materials. This composite approach maintains the NIR photoluminescence of SnS while adding stability and biocompatibility from the shell material.
2Ease of manufacture
If SnS QDs are synthesized without proper surface treatment, then synthesis simplicity is improved, but stability and photoluminescence properties deteriorate
Solution Approach 1:
The patent applies preliminary surface treatment during the synthesis process itself, where capping agents and stabilizing molecules are introduced concurrently with QD formation. This preliminary action ensures that stability and photoluminescence properties are built into the structure from the beginning, eliminating the need for separate post-synthesis treatment steps.
Solution Approach 2:
The patent uses capping agents and stabilizing molecules as intermediaries between the SnS QD core and the aqueous environment. These intermediary layers protect the QD surface, prevent aggregation, enhance stability, and improve water solubility without requiring complex multi-step surface modification procedures.
3Device complexity
If SnS QDs are synthesized without capping molecules and surface treatment, then manufacturing complexity is reduced, but photoluminescence intensity and stability decrease
Solution Approach 1:
The patent merges the synthesis step with the surface treatment step by introducing capping agents and stabilizing molecules during the QD formation process. This combined approach achieves both QD synthesis and surface functionalization in a single manufacturing step, maintaining simplicity while ensuring high photoluminescence intensity and stability.
Solution Approach 2:
The patent optimizes parameters such as capping agent concentration, pH, temperature, and reaction time to achieve simultaneous synthesis and surface treatment. By carefully controlling these parameters, the process achieves high photoluminescence intensity and stability without increasing manufacturing complexity.
4Object-affected harmful factors
If SnS QDs are used for in vivo imaging without proper surface modification, then biocompatibility is improved, but imaging precision and detection capability deteriorate
Solution Approach 1:
The patent modifies surface parameters by introducing functional groups (carboxyl, amine, hydroxyl) through capping agents and stabilizing molecules. These surface parameter changes enhance biocompatibility while simultaneously improving imaging precision through better target binding affinity and reduced non-specific binding.
Solution Approach 2:
The patent creates composite surface structures on SnS QDs by combining biocompatible coatings with targeting ligands. This composite surface architecture maintains low toxicity and high biocompatibility while adding specific binding capabilities that enhance imaging precision and detection capability for cancer cells and tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces SnS QDs with enhanced photoluminescence intensity and stability, reducing cytotoxicity and improving their suitability for NIR imaging applications, including deep tissue imaging and cancer cell membrane detection.
Implementation Method 1
quantum dots (QDs) are semiconductor nanocrystals that have distinctive photoluminescence properties. NIR QDs are suitable for in vivo deep tissue imaging since tissue absorbs only minimal amounts of light in the NIR wavelength range.
Implementation Method 2
reacting Sn2+ cations with S2− anions and a capping molecule in a water-miscible solvent to form capped SnS quantum dots
Data Source
AI summary
An aqueous approach to synthesize capped SnS quantum dots (QDs) followed by optional capping molecule extension by attaching one or more extending molecules to the capping molecule via peptide bond formation at elevated temperature. The capped SnS QDs may have a capping molecule:Sn:S molar ratio of 16:3:1 to 16:12:1. A suspension of SnS QDs was heat-treated at 200° C. for 0.5-4 hrs. The obtained SnS QDs showed an NIR emission peak at 820-835 nm with an excitation wavelength at 690 nm. The as synthesized SnS QDs were found to have high positive zeta potential of ˜30 mV and thus were toxic to cells. By neutralizing the SnS QDs the cytotoxicity was reduced to an accepted level. The heat-treatment step can be obviated by adding a glycerol solution containing S2− anions and capping molecule to a glycerol solution of Sn2+ ions.